11/11/2024 | Press release | Distributed by Public on 11/11/2024 06:04
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with[...]
